BioMab, Inc. is an immune-based precision medicine company based in Taiwan. Spun-out of Academia Sinica, our current product portfolio focuses on two primary areas of precision medicine: circulating tumor cell (CTC) and companion diagnostics (CDx). The company’s leading product is a Positive CTC Selection Assay, which can detect cancer through a simple blood draw.
CTC is an emerging field that will transform cancer diagnosis and treatment through simple blood draw (“Liquid Biopsy”). According to BBC Research, the global market for CTC is estimated to reach nearly US$8.9 billion by 2018, demonstrating a compound annual growth rate (CAGR) of 18.9% for the five-year period (2013 to 2018).The traditional cancer diagnosis involve surgical biopsy and CT scan, which are not only highly invasive, costly, and harmful to patients, but they can only detect cancers at later stage when it is already too late. CTC can be used regularly to monitor cancer survivors to prevent cancer recurrence, and it can also potentially provide a faster and cheaper way for early screening to help eliminate cancers before they start spreading.
Our second area of focus is immune-based companion diagnostics for use in conjunction with targeted therapies, such as antibody drugs, antibody drug conjugates (ADCs) and immunotherapies. According to Transparency Market Research, the global companion diagnostics market is estimated to value at $5.6 billion in 2019. It is expected to grow at a CAGR of 18.1% from 2013 to 2019, and was valued at $1.8 billion in 2013. BioMab, Inc. is developing a series of immune-based companion diagnostics and proprietary algorithms to facilitate new drugs/therapeutics development companies to maximize the clinical trial success rates for their new drug candidates.
We have established partnerships with several leading companies for product co-development and distribution. We and our collaborating partners use CTC reagent as our first product to build our company’s brand awareness and distribution channels targeting diagnostic market. We intend to leverage our strength in antibody/biological to screen additional antibodies against various cancers and infectious diseases to further build up our reagents/diagnostics pipelines, which can be rapidly launched to the market through established product development process and distribution channel.